Addex Says Parkinson’s Treatment Alleviates Symptoms in Trial

Addex Pharmaceuticals Ltd. (ADXN) said its experimental treatment for Parkinson’s disease reduced symptoms and was safe in a mid-stage patient study.

In a trial involving 76 Parkinson’s patients, dipraglurant showed a statistically significant reduction in the involuntary movements linked with the most widely used drug to treat the disease, Geneva-based Addex said in a statement after the close of trading today.

The drug also met its safety targets in the trial, Addex said.

Addex said today it’s changing its name to Addex Therapeutics. The switch has to be approved by shareholders.

To contact the reporter on this story: Simeon Bennett in Geneva at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.